Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine With GLA-SE for Resected Melanoma
NCT02320305Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of GLA-SE adjuvant in melanoma (2 arms), sponsored by Mayo Clinic. Primary endpoint: Immune response of each immunization regimen up to 24 months. Started Jan 2015; status: completed.
02
Drugs
GLA-SE adjuvant
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02320305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320305.